Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study
International Journal of Clinical Oncology · 2026
DOI: 10.1007/s10147-026-03056-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Ami Jo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2‑1‑1, Idaidori, Yahaba, Iwate, 028‑3695, Japan. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasm Recurrence, Local, Ovarian Neoplasms, Indazoles. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) rechallenge has been explored for platinum-sensitive recurrent ovarian cancer, data in Japanese patients remain scarce. This retrospective study evaluated the safety and efficacy of PARPi rechallenge in this population. PATIENTS AND METHODS: Twenty-eight Japanese patients with ovarian cancer who experienced platinum-sensitive recurrence during or after PARPi therapy and subsequently responded to platinum-based chemotherapy were included. Olaparib and niraparib were administered as PARPi rechallenge in 19 and 9 patients, respectively. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and adverse events (AEs). RESULTS: The median follow-up period was 19 months (range, 3-47). Median PFS and OS in the overall population were 6 months (95% CI, 3-8) and 32 months (95% CI, 28-not reached), respectively. The median PFS for patients who had received two prior regimens was 6 months, compared with 5 months for those who had received three or more regimens, with no significant difference (P = 0.734). Grade ≥3 hematologic toxicities included neutropenia (n = 4), anemia (n = 7), and thrombocytopenia (n = 2). Non-hematologic toxicities included interstitial pneumonia, hypertension, and proteinuria, with one case each. No treatment-related deaths occurred. CONCLUSIONS: PARPi rechallenge in Japanese patients with platinum-sensitive recurrent ovarian cancer demonstrated a manageable safety profile but limited efficacy. Larger, prospective studies incorporating molecular stratification are required to better define the clinical role of PARPi rechallenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2‑1‑1, Idaidori, Yahaba, Iwate, 028‑3695, Japan.
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2‑1‑1, Idaidori, Yahaba, Iwate, 028‑3695, Japan. tshoji@iwate-med.ac.jp.
- Department of Information Science, Iwate Medical University, Yahaba, Japan.
- Department of Obstetrics and Gynecology, Hachinohe Red Cross Hospital, Hachinohe, Japan.
Zitieren
APA
Jo, A., Shoji, T., Kitamura, A., Musashi, M., Tatsuki, S., Jonai, N., Chiba, Y., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., Takahashi, F., Aida, T., & Baba, T. (2026). Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03056-5
Vancouver
Jo A, Shoji T, Kitamura A, Musashi M, Tatsuki S, Jonai N, et al. Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03056-5
BibTeX
@article{Jo2026,
author = {Jo, Ami and Shoji, Tadahiro and Kitamura, Ayaka and Musashi, Miku and Tatsuki, Shunsuke and Jonai, Nanako and Chiba, Yohei and Sato, Sho and Takatori, Eriko and Kaido, Yoshitaka and Nagasawa, Takayuki and Kagabu, Masahiro and Takahashi, Fumiaki and Aida, Takeshi and Baba, Tsukasa},
title = {Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03056-5}
}
EUVIMED